HK Stock Market Move | HIGHTIDE-B (02511) rose more than 5% as the new drug application for HTD1801 was accepted by the National Medical Products Administration.

HIGHTIDE-B (02511) rose more than 5%, as of press time, it increased by 4.95% to HK$3.18, with a turnover of HK$1.534 million. On the news front, Junsentei Pharmaceuticals announced that the National Medical Products Administration (NMPA) of China has accepted the New Drug Application (NDA) for HTD1801 for the treatment of type 2 diabetes (T2DM). This is the first new drug application submitted by Junsentei Pharmaceuticals, and is an important milestone for the company's move towards product commercialization. HTD1801 has completed 3 multicenter, randomized, double-blind, controlled Phase III clinical studies for the indication of T2DM, all of which have met the primary endpoints and several secondary endpoints, showing consistent improvement trends in key dimensions of cardiovascular and renal metabolism such as blood sugar, blood lipids, inflammation, and kidney function, fully demonstrating its clinical value as a multi-effect, comprehensive benefit drug.